Oncology Business Management | Specialty

The Future Treatment of Follicular Lymphoma

January 5th 2018

Immunotherapy in the Treatment of Follicular Lymphoma

January 5th 2018

FL: Potential for SYK/JAK Inhibitors or Azacitidine

January 5th 2018

Novel Agents in FL: Unmet Needs and Potential Uses

January 5th 2018

Follicular Lymphoma: Novel Approaches With Rituximab

January 5th 2018

Follicular Lymphoma: Optimizing Novel Agent Therapy

January 5th 2018

Third-Line Treatment for FL: PI3 Kinase Inhibitors

January 5th 2018

Choosing Second-Line Therapy for Relapsed/Refractory FL

January 5th 2018

Predicting and Analyzing Response in Follicular Lymphoma

January 5th 2018

Challenging the Role of Maintenance Therapy in FL

January 5th 2018

Upfront Therapy Strategies in Follicular Lymphoma

January 5th 2018

Follicular Lymphoma: Outcomes After Immunochemotherapy

January 5th 2018

Hospital Cost Comparisons Should Be Fair

December 31st 2017

The debate continues to rage over whether the difference in the cost of oncologic care between outpatient hospital and physician private offices is appropriate.

Biomarker Testing Continues to Develop in NSCLC

December 28th 2017

Kathryn F. Mileham, MD, discusses the development of biomarker testing for patients with mutated non-small cell lung cancer.

Precision Medicine Can Help Reduce "Overdiagnosis" Problem

December 27th 2017

In patients with common solid tumors, it is well-established that those with early-stage cancers have a statistically defined superior prognosis compared with those who present with and are required to be treated at later stages of the disease.

Experts Discuss Ways to Remove Barriers to Optimal Management of CINV

December 26th 2017

Despite the widespread availability of antiemetic regimens, between 30% and 50% of patients receiving chemotherapy experience treatment-related nausea and/or vomiting.

Some Common Oncology Terms Carry Unanticipated Consequences

December 26th 2017

There are certain commonly used terms in the realm of oncology that may result in unintended consequences and should be considered carefully before being employed in conversation or in writing.

Proving That Value-Based Care Is Possible

December 25th 2017

More than 2 years after the passage of the Medicare Access and CHIP Reauthorization Act of 2015, the progression toward value-based care has challenged oncologists to assume an unprecedented degree of accountability for the well-being and holistic care of their patients.

Right-to-Try Bills Push the Needle on Risk

December 24th 2017

Congressional "right-to-try" legislation could make investigational drugs available to desperately ill patients sooner in the trials process, but there are substantial risks.

With the Aid of an Upgraded Acuity Tool, Fewer Patients Slip Through the Cracks

December 23rd 2017

A caseload management tool developed at the Mitchell Cancer Institute at the University of South Alabama offers a comprehensive portrait of a patient's condition that helps oncology nurse navigators to allocate their time and resources efficiently and enables managers to optimize patient care by assigning appropriate caseloads.